QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
NYSE:BTX

Brooklyn ImmunoTherapeutics (BTX) Stock Price, News & Analysis

$2.15
0.00 (0.00%)
(As of 04/18/2024 ET)
Today's Range
$2.06
$2.16
50-Day Range
$1.55
$4.10
52-Week Range
$0.17
$10.10
Volume
4,767 shs
Average Volume
515,543 shs
Market Capitalization
$126.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BTX stock logo

About Brooklyn ImmunoTherapeutics Stock (NYSE:BTX)

Eterna Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. The company is headquartered in San Diego, CA.

BTX Stock Price History

BTX Stock News Headlines

'Brooklyn Nine-Nine' star Andre Braugher dies at 61
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Brooklyn Bridge
Brooklyn Bedding Coupon for November
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Brooklyn Hospital Center
Brooklyn Technical High School
Brooklyn Preparatory High School
See More Headlines
Receive BTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Television Broadcasting
Sub-Industry
N/A
CIK
N/A
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$126.48 million
Optionable
No Data
Beta
4.61
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Matthew Angel
    President, Chief Executive Officer & Director
  • Andrew C. Jackson
    Chief Financial Officer
  • Roger Sidhu
    Chief Medical Officer
  • Jay Sial
    Chief Administrative Officer
  • Sandra Gurrola
    Principal Accounting Officer & VP-Finance

BTX Stock Analysis - Frequently Asked Questions

How have BTX shares performed in 2024?

Brooklyn ImmunoTherapeutics' stock was trading at $4.1020 on January 1st, 2024. Since then, BTX shares have decreased by 47.6% and is now trading at $2.15.
View the best growth stocks for 2024 here
.

How do I buy shares of Brooklyn ImmunoTherapeutics?

Shares of BTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners